

Special Issue

Mechanisms of Cell Death in Cancer Cells: A New Therapeutic Opportunity

Message from the Guest Editors

We are pleased to announce a new Special Issue in *Biomedicines* focused on the “Mechanisms of Cell Death in Cancer Cells: A New Therapeutic Opportunity”. Cancer initiation and progression are sustained by a series of broad alterations in molecular pathways as a result of genetic error, external stimuli, etc. One such pathway with crucial importance to human health is the mechanism of cell death. As such, multiple cancer-associated alterations have often been proven to modulate or even abrogate cell death. Therefore, targeting the molecular pathways which are directly or indirectly involved in the mechanism of cell death represents a potential therapeutic strategy for the development of efficient antitumor molecules. The Special Issue is meant to highlight outstanding research involving novel and previously described and repositioned therapeutic compounds which can target the mechanism of cell death in both solid and hematological malignancies.

Guest Editors

Dr. Adrian-Bogdan Țigu

Department of Translational Medicine, MEDFUTURE—Institute of Medical Research and Life Sciences, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania

Dr. Ciprian Tomuleasa

Department of Hematology, Institute of Oncology "Ion Chiricuta", University of Medicine and Pharmacy "Iuliu Hațieganu", 400012 Cluj-Napoca, Romania

Deadline for manuscript submissions

closed (31 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/123330

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).